卡培他滨相关基因多态性与手足综合征关系的研究进展

doi:10.11904/j.issn.1002-3070.2018.02.012

Abstract

Abstract: In recent years,capecitabine is widely used in clinical practice.Hand-foot syndrome is a dose-limiting toxicity,often manifested as numbness in the hands and feet,sensation of dullness,tingling,skin swelling or erythema,scaling,blisters or serious pain.Its occurrence has seriously affected the chemotherapy effect and daily life of patients.Genetic mutations of capecitabine metabolic enzymes play an important role in the drug efficacy and side-effect.In particular,the relationship between gene polymorphisms of CDA,CES,TP,DPD,TYMS,MTHFR and hand-foot syndrome has been widely investigated and achieved by researchers.This article reviews the relationship between capecitabine metabolizing enzymes and hand-foot syndrome in order to provide a reference for identifying the biological target of hand-foot syndrome caused by capecitabine chemotherapy.

Key words: Capecitabine, Adverse effects, Hand-foot syndrome, Gene polymorphism

CLC Number:

R968

LI Xiang, LIU Duo, WU Dongyuan, FAN Xiaofan, ZHANG Juan, DONG Mei. Research progress of relationship between capecitabine related gene polymorphisms and hand-foot syndrome[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 149-153.

References

1 侯婷,宋琼,任太娟,等.两种方法护理卡培他滨致手足综合征的疗效比较[J].分子影像学杂志,2017,40(2):239-241.
2 李洁,李忠.中医药防治卡培他滨所致手足综合征的研究进展[J].中医药信息,2012,29(4):166-168.
3 Nikolaou V,Syrigos K,Saif MW.Incidence and implications of chemotherapy related hand-foot syndrome[J].Expert Opin Drug Saf,2016,15(12):1625-1633.
4 Reichardt P,von Minckwitz G,Thuss PC,et al.Multicenter phase II study of oral capecitabine(Xeloda)in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy[J].Ann Oncol,2003,14(8):1227-1233.
5 Abushullaih S,Saad ED,Munsell M,et al.Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with Capecitabine:a single-institution experience[J].Cancer Invest,2002,20(1):3-10.
6 李玺,姜华,郭卫平,等.卡培他滨引起的手足综合征发病特点与治疗观察[J].中华临床医师杂志,2011,5(6):1781-1783.
7 郭千弘,马建瓴,张烔,等.卡培他滨与5-氟尿嘧啶引起手足综合征的临床观察[J].中国医药指南,2013,11(31):36-37.
8 Gao J,He Q,Hua D,et al.Polymorphism of TS 3′-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel[J].Clin Transl Oncol,2013,15(8):619-625.
9 童竹月,王彬彬.手足综合征的最新研究进展[J].浙江临床医学,2017,19(3):581-583.
10 Queckenberg C,Erlinghagen V,Baken BC,et al.Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations[J].Cancer Chemother Pharmacol,2015,76(5):1081-1091.
11 Lou Y,Wang Q,Zheng J.Possible pathways of capecitabine induced hand foot syndrome[J].Chem Res Toxicol,2016,29(10):1591-1601.
12 Mercier C,Dupuis C,Blesius A,et al.Early severe toxicities after capecitabine intake:possible implication of a cytidine deaminase extensive metabolizer profile[J].Cancer Chemother Pharmacol,2009,63(6):1177-1180.
13 Dahan L,Ciccolini J,Evrard A,et al.Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake:pharmacogenetic implications[J].J Clin Oncol,2012,30(4):41-44.
14 Caronia D,Martin M,Sastre J,et al.A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome[J].Clin Cancer Res,2011,17(7):2006-2013.
15 Pellicer M,García-González X,García MI,et al.Identification of new SNPs associated with severe toxicity to capecitabine[J].Pharmacol Res,2017,120:133-137.
16 García-González X,Cortejoso L,García MI,et al.Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer[J].Oncotarget,2015,6(8):6422-6430.
17 Martín M,Martínez N,Ramos M,et al.Standard versus continuous administration of capecitabine in metastatic breast cancer(GEICAM/2009-05):a randomized,non inferiority phase II trial with a pharmacogenetic analysis[J].Oncologist,2015,20(2):111-112.
18 Hamzic S,Kummer D,Milesi S,et al.Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity[J].Clin Pharmacol Ther,2017,102(5):796-804.
19 Lindskog EB,Derwinger K,Gustavsson B,et al.Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer[J].BMC Clin Pathol,2014,14(1):25.
20 Huang L,Chen F,Chen Y,et al.Thymidine phosphorylase gene variant,platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidines[J].Sci Rep,2014,4:5697.
21 Rosmarin D,Palles C,Pagnamenta A,et al.A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS[J].Gut,2015,64(1):111-120.
22 Yap YS,Kwok LL,Syn N,et al.Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine induced hand-foot syndrome:a randomized clinical trial[J].JAMA Oncol,2017,3(11):1538-1545.
23 Hammad H,Sarkar M,Subbarayan PR,et al.Thymidylate synthase 5′UTR polymorphic allele distribution in south florida population[J].J Cancer Ther,2012,3(2):173-176.
24 Thomas F,Hoskins JM,Dvora A,et al.Detection of the G＞C SNP and rare mutations in the 28 bp repeat of TYMS using gel-based capillary electrophoresis[J].Pharmacogenomics,2010,11(12):1751-1756.
25 Rosmarin D,Palles C,Church D.Genetic of toxicity from capecitabine and other fluorouracil based regimens:investigation in the QUASAR2 study,systematic review,and meta-analysis[J].J Clin Oncol,2014,32(10):1031-1039.
26 Matsusaka S,Lenz HJ.Pharmacogenomics of fluorouracil-based chemotherapy toxicity[J].Expert Opin Drug Metab Toxicol,2015,11(5):811-821.
27 Iacopetta B.Methyl-group metabolism and response of colorectal cancer to 5-fluorourail[J].Crit Rev Oncog,2006,12(1/2):115-126.
28 Loganayagam A,Arenas Hernandez M,Corrigan A,et al.Pharmacogenetic variants in the DPYD,TYMS,CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity[J].Br J Cancer,2013,108(12):2505-2515.
29 Roberto M,Romiti A,Botticelli A.Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine[J].Eur J Clin Pharmacol,2017,73(2):157-164.
30 Sharma R,Hoskins JM,Rivory LP,et al.Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients[J].Clin Cancer Res,2008,14(3):817-825.

[1]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[2]	CHEN Long,QIAN Cheng. Research advances on the relations of vascular endothelial growth factor polymorphisms and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(3): 284-286.
[3]	CHEN Jie,HOU Encun. Advances in bevacizumab combined with XELOX regimen in the treament of metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 157-161.
[4]	LIU Lei, GU Manling. Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(1): 62-63.
[5]	ZHANG Mingkui, JIANG Hua, SUN Yunliang. Clinical observation on irinotecan and capecitabine in the treatment of advanced or mestastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(5): 451-453.
[6]	YUE Xiaolong, LIU Wenming. Comparative study of drug combination of CPT-11 plus CAP and 5-Fu/CF in the treatment of advanced colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 336-338.
[7]	MA Jingguang, XING Lina, LIU Xiao, DONG Guanglu, LIU Xiaobin, WEI Xing. Result of capecitabine and nedaplatin combined with concurrent radiotherapy for recurrent cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 346-348.
[8]	GAO Fei, JIA Lin, DU Huizhang, WANG Yun, KUANG Xiaohong, HAN Jianjun. A clinical study of combination of radiotherapy and IP regimen in the treatment of patients with local advanced esophageal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(2): 126-129.

Research progress of relationship between capecitabine related gene polymorphisms and hand-foot syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 8

Recommended Articles

Metrics

Comments